Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CNAT getting action today
OCRX +16% :)
OCRX $5.49 "Biotech Stocks With Up to 200% Upside"
http://247wallst.com/healthcare-business/2014/11/21/4-more-biotech-stocks-with-up-to-200-upside/
CCXI- FDA Orphan Designation for atypical hemolytic uremic syndrome treatment ... Don't see PR yet from company.. Orphan Designation awarded Nov 17 on FDA website
http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=443714
CNAT $7.08-Back in on this one. Starter position for now. Will add on dips. Indeed very busy next 4-6 months for this company.
TRVN $6.20-"Trevena Announces Positive Top-Line Results from Phase 2a/b Study of TRV130 in Acute Postoperative Pain"--- News Yesterday after market close.. Looks good .. Never seen this stock mentioned here...i am new to this myself...Please share your thoughts if you know anything.. Thanks.
http://finance.yahoo.com/news/trevena-announces-positive-top-line-210100254.html
JMP upgraded raised PT $21 this morning.
http://www.americanbankingnews.com/2014/11/18/trevena-price-target-raised-to-21-00-at-jmp-securities-trvn/
Also Needham & Company Reiterates Bullish Stance on Trevena $TRVN Amid Positive TRV130 Phase 2b-- PT $14
http://www.streetinsider.com/Analyst+Comments/Needham+%26+Company+Reiterates+Bullish+Stance+on+Trevena+%28TRVN%29+Amid+Positive+TRV130+Phase+2b+Bunionectomy+Results/10024930.html
TLOG-Fantastic winner. Thank you !
TLOG yes i really like this one here at this price. Risk/Reward seems to be solid. I liked the insider buys last week. Nice swing position for me.
HOTR $1.86-Added long position here. This one operates hooters restaurant and the revenue increased nicely and seethruEquity gave a $5 price target this morning. This one is a low floater that could make moves fast.
http://finance.yahoo.com/news/seethruequity-issues-chanticleer-holdings-increases-140000260.html
LPCN $4.90 here added yesterday thin one. I like the risk/reward as i said here
CYTX $0.43 +13%<-$0.395 add
CYTX-CEO & CFO insider purchase last 2 days FORM 4 out
TLOG-anoter CEO purchase today 10k shares
http://ih.advfn.com/p.php?pid=nmona&article=64400835&xref=newsalerttweet&adw=1126416
TLOG-$3.99 some DD and Insider purchase reported today.
Reported today 11/12/2014: Paul J. Schmitt Acquires 20,000 Shares of Tetralogic Pharmaceuticals Corp Stock (TLOG)
"Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) Director Paul J. Schmitt acquired 20,000 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was purchased at an average price of $4.10 per share, with a total value of $82,000.00. "
Read more here; http://www.wkrb13.com/markets/422710/insider-buying-paul-j-schmitt-acquires-20000-shares-of-tetralogic-pharmaceuticals-corp-stock-tlog/
Pipeline:
ONCOLOGY PRE-CLINICAL PHASE 1 PHASE 2
Myelodysplastic Syndromes (MDS) Birinapant
Cutaneous T-Cell Lymphoma (CTCL) SHAPE
Colorectal Cancer (CRC) Birinapant
Ovarian Cancer Birinapant
INFECTIOUS DISEASE
Hepatitis B Birinapant
More here: http://tetralogicpharma.com/clinical-trials/
Market Cap (yahoo): $88.59M
Cash as of Sept 30,2014 = $65.1 M
"Cash, cash equivalents, and marketable securities totaled $65.1 million at September 30, 2014, as compared to $55.1 million at December 31, 2013. "
Catalysts:
*** Birinapant/conatumumab Program: Enrollment continues in a signal-seeking study in combination with conatumumab, Amgen's TRAIL agonist antibody, in 3rd line ovarian cancer. We currently expect data around the end of 2014.
****Birinapant HBV Program:We are commencing enrollment in a multiple ascending dose study of birinapant in subjects with chronic hepatitis B in the fourth quarter of 2014. We currently expect data to be generated around the middle of 2015.
Birinapant MDS Program: "We currently expect interim data from the Phase 2 study in the middle of 2015."
SHAPE CTCL Program: "We are advancing SHAPE into a randomized Phase 2 clinical trial in early stage CTCL. We currently expect data around the end of 2015.
Share structure:
"Shares issued and outstanding as of September 30, 2014 were 22.3 million, not including outstanding stock options to purchase 3.2 million shares and 7.0 million shares underlying the company's outstanding convertible notes."
chart looks like it has bottomed out:
http://finviz.com/quote.ashx?t=TLOG
LPCN $4.60-Added some long position on this one today. Really like the risk/reward here on their Oral T drug. Excellent phase 3 results recently. and this zacks report published yesterday with PT $13.50 on this one.
Lipocine's Oral TRT Drug Too Attractive To Ignore
http://finance.yahoo.com/news/lipocines-oral-trt-drug-too-153000253.html
LPCN-"Lipocine's Oral TRT Drug Too Attractive To Ignore" -New article by Jason Napodano $13.50 PT . This one is also a low floater .
http://bionapcfa.blogspot.com/2014/11/lipocines-oral-trt-drug-too-attractive.html
CYTX-Added $0.395....Like the price
OCRX $5.67 Really like this one for Q1 play. adding on the dips on this one slowly.
PTN $0.63->$0.79 was on watch few days ago.
CNAT $6.80 This one hit as high as $7.80 just last week. With catalyst coming up expecting this to move up from here.
DARA-looking good here. Earnings tomorrow i believe.
$OXGN-Catalyst approaching very fast, have to agree this could make moves here
PTN $0.63 on watch for bottom
OCRX-(OCRX)’s New HE Drug Could Pull Stock Up Out Of Rut: Cowen - See more at: http://www.biospace.com/News/ocera-therapeutics-inc-s-new-he-drug-could-pull/351405#sthash.awEHQ3nP.dpuf
CYTX $0.54 +7% big volume and trying to breakout here today
CYTX $0.495 watching for bottom reversal here. Nice volume today
definitely will be interesting sheff. spec money is coming back, if we catch some shorts into covering could see some nice short covering rally. Waiting !
CYTX $0.48 Bottom Reversal possible here too imo.. BAXS huge reversal.
BAXS $0.22 +40% sold all here. I did buy more last week around $0.12
RGDO $1.10 on watch here. They have big cash position and trading way under cash position here.
OCRX-This is going to be solid play soon heading into Q1 imo. Link back for some highlights.
CYTX-$0.47 Added long position here. Like the price here. Looks oversold.
CEMI$4.61-Chembio Partners With Integrated BioTherapeutics, Inc. to Develop Point-of-Care Diagnostic Tests for Ebola and Febrile Illness
Volume is big on this thinly traded stock.
http://finance.yahoo.com/news/chembio-partners-integrated-biotherapeutics-inc-125000536.html
OXGN- Adam Feuerstein wrote a very nice article this morning. Very important time for OXGN, next 3-4 weeks very interesting and the upside is huge imo.
http://www.thestreet.com/story/12924666/1/biotech-stock-mailbag-rockwell-medical-oxigene-prosensa-sarepta.html
CNAT-Biotech Firm Hopes to Make Big Splash with Liver Disease Treatments
http://emerginggrowth.com/financial/biotech-firm-hopes-to-make-big-splash-with-liver-disease-treatments/10/23/2014/
GBLX expecting Nevada state license on or before Nov 03, 2014 FYI
GBLX expecting Nevada state license on or before Nov 03, 2014 FYI
GBLX could catch marijuana momentum imo
GBLX- watching this one to go with HEMP MJNA etc